Interestingly, daily injections of the non-selective P2X7 antagonist pyridoxalphosphate-6-axophenyl-2′-4′-disulfonic acid [132] at 300 mg/kg (Days 0–10) only partly reduced GVHD [129]. This evidence concerns the gene P2RX7 and graft versus host disease.